Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
暂无分享，去创建一个
J. Crowley | G. Demetri | R. Maki | M. Heinrich | C. Blanke | M. von Mehren | C. Fletcher | J. Hecht | R. Benjamin | C. Rankin | E. Borden | C. Ryan | V. Bramwell | L. Baker | A. K. Raymond | C. Blanke | Michael S. Tanaka | A. Raymond | Michael S Tanaka | Christopher D.M. Fletcher | Christopher D.M. Fletcher | C. D. Fletcher